We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
A picture of Anna MacDonald

Anna MacDonald profile page

Senior Science Editor

 at Technology Networks


After obtaining a first-class honors degree in biological sciences from the University of East Anglia, Anna worked as a scientific conference producer before joining Technology Networks. As part of her role, Anna helps to coordinate coverage, working with key opinion leaders from industry and academia to produce content across all communities.


Education


University of East Anglia  


Areas of Expertise



Got a Question for Anna MacDonald?


Get in touch using the contact form linked here and we’ll get back to you shortly



Published Content
Total: 323
Male scientist looking into a microscope situated next to an assortment of fruit, vegetables, eggs and meat.
Industry Insight

Inside RAFA 2024: A Conversation With Event Chairs on Food Analysis Breakthroughs and Challenges

In this interview, two of the RAFA 2024 chairs discuss the key themes that will be covered at the event and share their thoughts on what the future holds for the food analysis field.
Collection of blue cells on a pink and white background.
Industry Insight

Advancing Cellular Analysis With Spectral Flow Cytometry

In this interview, Xiaobo Wang discusses some of the NovoCyte Opteon’s advanced spectral capabilities and how they help to address existing challenges in flow cytometry.
Whole and halved strawberries
Industry Insight

New Developments in Analytical Systems May Aid the “Fight” Against PFAS

Technology Networks recently spoke with Dr. Holly Lee and Dr. Craig Butt from SCIEX to learn more about the analytical challenges of detecting PFAS and SCIEX’s 7500+ system to aid developments in mass spectrometry.
Artificial intelligence brain on computerized network background
Industry Insight

The Adoption of AI: Critical Concerns in the Life Sciences

In this interview, Dr. Becky Upton discusses the key findings of a recent survey conducted by the Pistoia Alliance regarding the use of AI in life sciences and the main hurdles preventing wider adoption of AI in pharma.

Cryopreservation infographic snippet.
Infographic

Cryopreservation: Key Principles and Recent Advances

Cryopreservation has played a critical role in biomedical research for many decades. This infographic explores some of the key principles of cryopreservation and highlights recent advances in this field.

Therapeutic drugs next to a stethoscope and target with a dart in the bullseye.
Industry Insight

Expanding the Druggable Space With Degradation-Based Therapies

We spoke with Dr. Christian Dillon to learn more about degradation-based therapies, the challenges associated with their discovery and how innovative solutions are helping to realize the potential of this promising class of therapeutics.
Snippet of the cell culture quality control infographic.
Infographic

Cell Culture Quality Control

Download this infographic to explore why quality control is key, the importance of cell line authenticity and how to reduce the risk of microbial contamination.
Close up view of the cathode end of a group of batteries.
Industry Insight

Improving Battery Analysis With Simultaneous Rheology and Impedance Measurements

Sarah Cotts tells us more about the Rheo-Impedance accessory and how it can help overcome limitations with current analysis approaches to improve battery development.

Dr. Sarah Teichmann standing next to a building and pond.
Article

From School Science Club to Cell Atlasing With Dr. Sarah Teichmann

In this interview, Dr. Sarah Teichmann shares insights into her research interests, the goals and progress of the HCA to date, as well as her thoughts on how women can begin and build successful careers in science.
Ribosome translating mRNA into a polypeptide chain.
Industry Insight

Tuning the Therapeutic Properties of tRNAs To Treat Rare Diseases

Michelle C. Werner discusses how tRNAs could transform the drug development paradigm from gene-centric to gene-agnostic and accelerate new therapies for 30 million or more patients whose genetically driven disease can be classified under Stop Codon Disease.
Advertisement